IRIDEX Corporation IRIX
Nov 6, 2026, 3:08 PM EST
- YTD
- -40.73%
- 1 year
- -35.65%
- Market cap
- 11.87M
- Revenue (ttm)
- 48.43M
- Profit margin
- -22.79%
- EPS (ttm)
- -0.20
- Shares out
- 16.64M
- Forward P/E
- -5.85
- YTD return
- -40.73%
- 1-year return
- -35.65%
- Volume
- 20.84K
- Avg volume
- 391.55K
- Open
- 0.69
- Previous close
- 0.68
- Day's range
- 0.6605 – 0.70
- 52-week range
- 0.61 – 1.65
2Y -0.7243 (-51.74%)
Key statistics
- Enterprise value
- 28.33M
- PEG ratio
- 0.00
- Price / sales
- 0.54
- Price / book
- 10.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -9.90%
- Free cash flow
- -1.40M
- Total cash
- 3.86M
- Total debt
- 4.91M
- Return on equity
- -150.28%
- Short % of float
- 1.83%
- 50-day average
- 1.65
- 200-day average
- 2.14
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.12 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.12 | -0.16 | -0.04 | -33.33% |
| May 14, 2024 | Mar 1, 2024 | -0.12 | -0.21 | -0.09 | -75.00% |
| Mar 26, 2024 | Dec 1, 2023 | -0.05 | -0.18 | -0.13 | -260.00% |
| Nov 14, 2023 | Sep 1, 2023 | -0.13 | -0.11 | +0.02 | +15.38% |
| Aug 10, 2023 | Jun 1, 2023 | -0.11 | -0.17 | -0.06 | -54.55% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 15, 2024 | Stifel | main | Hold | Hold |
| Aug 26, 2022 | Stifel | down | Buy | Hold |
| May 12, 2021 | Roth Capital | main | — | Buy |
| Mar 3, 2021 | Roth Capital | main | — | Buy |
| Jan 13, 2021 | Roth Capital | main | — | Buy |
| May 12, 2020 | Stifel | main | — | Buy |
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- iridex.com
News
Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026
12 Health Care Stocks Moving In Monday's Pre-Market Session Iridex Announces Publication Of 2-Yr Clinical Study Demonstrating Favorable Outcomes With TLT Using MicroPulse Technology In Patients With Primary Glaucoma
12 Health Care Stocks Moving In Wednesday's Intraday Session
Full Transcript: Iridex Q2 2026 Earnings Call Iridex Affirms FY2026 Sales Guidance of $51.000M-$53.000M vs $53.227M Est
Iridex Q2 EPS $(0.07) Misses $(0.01) Estimate, Sales $12.566M Miss $13.587M Estimate
12 Health Care Stocks Moving In Monday's After-Market Session Iridex Expands Its EyeProGPO Product Offering To Include The Company’s Line Of EndoProbe Handpieces
Iridex Q1 2026 Earnings Call: Complete Transcript
Your note
Sign in to keep a note on IRIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEVI NANDINI | Director | Stock Award(Grant) | Jun 13, 2023 | 77,159 |
| GROVE ROBERT EARLE | Director | Stock Award(Grant) | Jun 13, 2023 | 160,103 |
| HUSS BEVERLY A | Director | Stock Award(Grant) | Jun 13, 2023 | 66,739 |
| LUDLUM KENNETH E. | Director | Stock Award(Grant) | Jun 13, 2023 | 101,711 |
| MERCER PATRICK | Chief Executive Officer | Stock Award(Grant) | Nov 6, 2024 | 393,244 |
| SHUDA SCOTT A | Director | Stock Award(Grant) | Jun 13, 2023 | 108,066 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Paragon Associates & Paragon Associates Ii Joint Venture | 6.01% | 1,000,000 | 1.58M | Sep 29, 2024 |
| Vanguard Group Inc | 3.37% | 561,096 | 886.53K | Sep 29, 2024 |
| AMH Equity Ltd. | 3.01% | 501,121 | 791.77K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.39% | 397,360 | 627.83K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.79% | 131,172 | 207.25K | Sep 29, 2024 |
| ARS Investment Partners, LLC | 0.68% | 113,565 | 179.43K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.27% | 376,944 | 595.57K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.99% | 164,113 | 259.30K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.45% | 75,000 | 118.50K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 71,096 | 112.33K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.20% | 33,602 | 53.09K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 16,065 | 25.38K | Oct 30, 2024 |
